Merck Sharp + Dohme Corp.

Ronald D Ferguson

David James Witter

Xianhai Huang

Jongwon Lim

Kevin J Wilson

Phieng Siliphaivanh

Christopher W Boyce

Milana M Maletic

Wei Zhou

Joseph A Kozlowski

David L Sloman

Joey Lee Methot

David Joseph Guerin

Umar Faruk Mansoor

Alessia Petrocchi

Christian Fischer

Matthew H Daniels

Corey E Bienstock

Salem Fevrier

Elizabeth Helen Kelley

Danielle Falcone

Brendan O'Boyle

Kathryn Ann Lipford

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I).

Compounds that are ERK inhibitors

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I). 

Disclosed are the ERK inhibitors of formula (I) and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I). This invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of formula (I) and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier. This invention also provides a method of inhibiting ERK (i.e., inhibiting the activity of ERK2) in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of formula (I). 

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1). 

Growing community of inventors

Scotch Plains, NJ, United States of America

Ronald D Ferguson